Belizan J.M.,Institute for Clinical Effectiveness and Health Policy |
Mumford S.,National Health Research Institute
Reproductive Health | Year: 2015
The editors of Reproductive Health would like to extend a sincere thank you to all our valued reviewers listed below who contributed to the journal in Volume 11 (2014). The journal has grown 63% in submissions and 43% in publications compared to 2013 and therefore the co-operation and dedicated time of peer reviewers is increasingly essential in order to move these manuscripts through the submission system so high quality research does not remain static and unpublished. We are very pleased to have a diverse range of reviewers from high, middle and low income countries, contributing to the dissemination of research findings in an open access journal. Please accept our sincerest and deepest thanks for your knowledge, time and continuing efforts. © 2015 Belizán et al.; licensee BioMed Central.
Requejo J.H.,Institute for International Programs |
Belizan J.M.,Institute for Clinical Effectiveness and Health Policy
Reproductive Health | Year: 2013
The last innovation in operative vaginal delivery happened centuries ago with the invention of the forceps and the vacuum extractor. The World Health Organization Odon Device Research Group recently published a protocol for a feasibility and safety study for a new device (Odon device) which aims to revolutionize assisted vaginal delivery. This editorial discusses the device and its pathway to global use. Although preliminary results look promising, the rigorous three-phased WHO protocol needs completion before the device can be determined, based on the evidence, to be safe and effective. © 2013 Requejo and Belizán; licensee BioMed Central Ltd.
Sullivan S.D.,University of Washington |
Mauskopf J.A.,RTI Health Solutions |
Augustovski F.,Institute for Clinical Effectiveness and Health Policy |
Jaime Caro J.,Evidera |
And 6 more authors.
Value in Health | Year: 2014
Background Budget impact analyses (BIAs) are an essential part of a comprehensive economic assessment of a health care intervention and are increasingly required by reimbursement authorities as part of a listing or reimbursement submission. Objectives The objective of this report was to present updated guidance on methods for those undertaking such analyses or for those reviewing the results of such analyses. This update was needed, in part, because of developments in BIA methods as well as a growing interest, particularly in emerging markets, in matters related to affordability and population health impacts of health care interventions. Methods The Task Force was approved by the International Society for Pharmacoeconomics and Outcomes Research Health Sciences Policy Council and appointed by its Board of Directors. Members were experienced developers or users of BIAs; worked in academia and industry and as advisors to governments; and came from several countries in North America and South America, Oceania, Asia, and Europe. The Task Force solicited comments on the drafts from a core group of external reviewers and, more broadly, from the membership of the International Society for Pharmacoeconomics and Outcomes Research. Results The Task Force recommends that the design of a BIA for a new health care intervention should take into account relevant features of the health care system, possible access restrictions, the anticipated uptake of the new intervention, and the use and effects of the current and new interventions. The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs. Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders. In instances, however, in which the changes in eligible population size, disease severity mix, or treatment patterns cannot be credibly captured by using the cost calculator approach, a cohort or patient-level condition-specific model may be used to estimate the budget impact of the new intervention, accounting appropriately for those entering and leaving the eligible population over time. In either case, the BIA should use data that reflect values specific to a particular decision maker's population. Sensitivity analysis should be of alternative scenarios chosen from the perspective of the decision maker. The validation of the model should include at least face validity with decision makers and verification of the calculations. Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible. Other data sources include the use of published data, well-recognized local or national statistical information, and, in special circumstances, expert opinion. Reporting of the BIA should provide detailed information about the input parameter values and calculations at a level of detail that would allow another modeler to replicate the analysis. The outcomes of the BIA should be presented in the format of interest to health care decision makers. In a computer program, options should be provided for different categories of costs to be included or excluded from the analysis. Conclusions We recommend a framework for the BIA, provide guidance on the acquisition and use of data, and offer a common reporting format that will promote standardization and transparency. Adherence to these good research practice principles would not necessarily supersede jurisdiction-specific BIA guidelines but may support and enhance local recommendations or serve as a starting point for payers wishing to promulgate methodology guidelines. © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Goldenberg R.L.,Drexel University |
McClure E.M.,University of North Carolina at Chapel Hill |
Bhutta Z.A.,Aga Khan University |
Belizan J.M.,Institute for Clinical Effectiveness and Health Policy |
And 6 more authors.
The Lancet | Year: 2011
Stillbirth is a common adverse pregnancy outcome, with nearly 3 million third-trimester stillbirths occurring worldwide each year. 98 occur in low-income and middle-income countries, and more than 1 million stillbirths occur in the intrapartum period, despite many being preventable. Nevertheless, stillbirth is practically unrecognised as a public health issue and few data are reported. In this final paper in the Stillbirths Series, we call for inclusion of stillbirth as a recognised outcome in all relevant international health reports and initiatives. We ask every country to develop and implement a plan to improve maternal and neonatal health that includes a reduction in stillbirths, and to count stillbirths in their vital statistics and other health outcome surveillance systems. We also ask for increased investment in stillbirth-related research, and especially research aimed at identifying and addressing barriers to the aversion of stillbirths within the maternal and neonatal health systems of low-income and middle-income countries. Finally, we ask all those interested in reducing stillbirths to join with advocates for the improvement of other pregnancy-related outcomes, for mothers and their offspring, so that a united front for improved pregnancy and neonatal care for all will become a reality. © 2011 Elsevier Ltd.
Mazzoni A.,Institute for Clinical Effectiveness and Health Policy |
Althabe F.,Institute for Clinical Effectiveness and Health Policy |
Liu N.H.,University of Nebraska - Lincoln |
Bonotti A.M.,Maternal and Child Health Program |
And 3 more authors.
BJOG: An International Journal of Obstetrics and Gynaecology | Year: 2011
Background The striking increase in caesarean section rates in middle- and high-income countries has been partly attributed to maternal request. We conducted a systematic review and meta-analysis of women's preferences for caesarean section. Objectives To review the published literature on women's preferences for caesarean section. Search strategy A systematic search of MEDLINE, EMBASE, LILACS and PsychINFO was performed. References of all included articles were examined. Selection criteria We included studies that quantitatively evaluated women's preferences for caesarean section in any country. We excluded articles assessing health providers' preferences and qualitative studies. Data collection and analysis Two reviewers independently screened abstracts of all identified citations, selected potentially eligible studies, and assessed their full-text versions. We conducted a meta-analysis of proportions, and a meta-regression analysis to determine variables significantly associated with caesarean section preference. Main results Thirty-eight studies were included (n = 19 403). The overall pooled preference for caesarean section was 15.6% (95% CI 12.5-18.9). Higher preference for caesarean section was reported in women with a previous caesarean section versus women without a previous caesarean section (29.4%; 95% CI 24.4-34.8 versus 10.1%; 95% CI 7.5-13.1), and those living in a middle-income country versus a high-income country (22.1%; 95% CI 17.6-26.9 versus 11.8%; 95% CI 8.9-15.1). Authors' conclusions Only a minority of women in a wide variety of countries expressed a preference for caesarean delivery. Further research is needed to better estimate the contribution of women's demand to the rising caesarean section rates. © RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology.